drugset / Trial / NCT02964910

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )

NCT02964910

Phase 4 Completed 475 enrolled Xiamen Innovax Biotech Co., Ltd
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This phase IV clinical study was designed to evaluate the immunogenicity and safety of Hecolin® in the chronic Hepatitis B patients on the clinical stability.

Timeline

Start
2016-08
Primary completion
2017-08
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hecolin® Vaccine Intramuscular